BridgeBio Pharma, Inc. (BBIO) › Cash & EquivalentsBridgeBio Pharma, Inc. (BBIO) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2017-12-31: $92.00M2018-12-31: $436.09M2019-12-31: $363.77M2020-12-31: $356.08M2021-12-31: $393.77M2022-12-31: $376.69M2023-12-31: $375.94M2024-12-31: $681.10M2025-12-31: $570.12M$570.12M2017-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$570.12M-16.3%2026-02-24Balance as of period end2024-12-31$681.10M+81.2%2026-02-24Balance as of period end2023-12-31$375.94M-0.2%2026-02-24Balance as of period end2022-12-31$376.69M-4.3%2025-02-20Balance as of period end2021-12-31$393.77M+10.6%2024-02-22Balance as of period end2020-12-31$356.08M-2.1%2023-02-23Balance as of period end2019-12-31$363.77M-16.6%2022-02-25Balance as of period end2018-12-31$436.09M+374.0%2021-02-25Balance as of period end2017-12-31$92.00M—2020-03-03Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)